This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

DSM-Firmenich Future Growth

Future criteria checks 4/6

DSM-Firmenich is forecasted to grow earnings and revenue by 20.5% and 11.1% per annum respectively. EPS is expected to grow by 18.3%. Return on equity is forecast to be 6.1% in 3 years.

Key information

20.5%

Earnings growth rate

18.3%

EPS growth rate

Chemicals earnings growth	21.0%
Revenue growth rate	11.1%
Future return on equity	6.1%
Analyst coverage	Good
Last updated	31 May 2023

Recent future growth updates

Recent updates

Does This Valuation Of Koninklijke DSM N.V. (AMS:DSM) Imply Investors Are Overpaying?

Aug 24

Koninklijke DSM (AMS:DSM) Has A Pretty Healthy Balance Sheet

Jun 29

Koninklijke DSM N.V.'s (AMS:DSM) Intrinsic Value Is Potentially 17% Below Its Share Price

May 24

Is Koninklijke DSM (AMS:DSM) A Risky Investment?

Mar 29

Should Koninklijke DSM N.V. (AMS:DSM) Be Part Of Your Dividend Portfolio?

Mar 15

Are Koninklijke DSM N.V.'s (AMS:DSM) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Mar 01

Koninklijke DSM (AMS:DSM) Has Gifted Shareholders With A Fantastic 276% Total Return On Their Investment

Feb 16

Need To Know: Koninklijke DSM N.V. (AMS:DSM) Insiders Have Been Selling Shares

Feb 04

Earnings and Revenue Growth Forecasts

ENXTAM:DSM - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	14,665	1,014	749	1,987	8
12/31/2024	13,934	685	847	1,966	9
12/31/2023	12,024	544	344	1,311	9
12/31/2022	8,390	454	314	965	N/A
9/30/2022	9,582	837	412	1,056	N/A
6/30/2022	9,802	1,082	510	1,147	N/A
3/31/2022	9,503	1,081	680	1,287	N/A
12/31/2021	7,269	820	850	1,427	N/A
9/30/2021	7,955	660	884	1,507	N/A
6/30/2021	7,558	493	906	1,489	N/A
3/31/2021	7,572	423	906	1,497	N/A
12/31/2020	8,106	448	868	1,494	N/A
9/30/2020	7,960	510	809	1,434	N/A
6/30/2020	8,034	557	810	1,462	N/A
3/31/2020	9,011	722	826	1,471	N/A
12/31/2019	7,998	675	744	1,385	N/A
9/30/2019	8,272	820	766	1,399	N/A
6/30/2019	8,502	794	747	1,395	N/A
3/31/2019	9,124	934	612	1,282	N/A
12/31/2018	9,267	1,069	698	1,391	N/A
9/30/2018	9,235	984	657	1,310	N/A
6/30/2018	9,106	2,082	550	1,170	N/A
3/31/2018	8,908	1,942	512	1,110	N/A
12/31/2017	8,632	1,761	441	996	N/A
9/30/2017	8,471	1,676	431	993	N/A
6/30/2017	8,333	738	470	1,028	N/A
3/31/2017	8,166	711	554	1,077	N/A
12/31/2016	7,920	645	523	1,018	N/A
9/30/2016	7,831	588	N/A	958	N/A
6/30/2016	7,778	274	N/A	914	N/A
3/31/2016	7,749	214	N/A	811	N/A
12/31/2015	7,722	174	N/A	696	N/A
9/30/2015	7,607	66	N/A	800	N/A
6/30/2015	7,456	114	N/A	820	N/A
3/31/2015	7,245	115	N/A	867	N/A
12/31/2014	7,051	123	N/A	808	N/A
9/30/2014	7,415	112	N/A	866	N/A
6/30/2014	7,834	138	N/A	885	N/A
3/31/2014	8,362	182	N/A	1,010	N/A
12/31/2013	8,858	252	N/A	998	N/A
9/30/2013	8,409	363	N/A	705	N/A
6/30/2013	8,500	335	N/A	638	N/A
3/31/2013	8,486	257	N/A	584	N/A
12/31/2012	8,588	280	N/A	730	N/A
9/30/2012	9,089	453	N/A	950	N/A
6/30/2012	9,107	543	N/A	1,020	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DSM's forecast earnings growth (20.5% per year) is above the savings rate (0.4%).

Earnings vs Market: DSM's earnings (20.5% per year) are forecast to grow faster than the Dutch market (16.1% per year).

High Growth Earnings: DSM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: DSM's revenue (11.1% per year) is forecast to grow faster than the Dutch market (3.9% per year).

High Growth Revenue: DSM's revenue (11.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DSM's Return on Equity is forecast to be low in 3 years time (6.1%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/05/31 03:02
End of Day Share Price	2023/05/30 00:00
Earnings	2022/12/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DSM-Firmenich AG is covered by 61 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Mutlu Gundogan	ABN AMRO Bank N.V.
Martin Schnee	AlphaValue
Volker Bosse	Baader Helvea Equity Research

This company listing is no longer active

DSM-Firmenich Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 59%, revenue upgraded

Consensus revenue estimates increase by 42%

Consensus EPS estimates fall by 38%

Consensus EPS estimates fall by 10%

Consensus forecasts updated

Consensus EPS estimates fall by 17%

Recent updates

DSM-Firmenich AG has completed a Follow-on Equity Offering in the amount of €733.264232 million.

Consensus EPS estimates fall by 59%, revenue upgraded

Analyst Forecasts For Koninklijke DSM N.V. (AMS:DSM) Are Surging Higher

Consensus revenue estimates increase by 42%

Key Executive recently sold €438k worth of stock

Consensus EPS estimates fall by 38%

Koninklijke DSM (AMS:DSM) Is Reinvesting At Lower Rates Of Return

Is Koninklijke DSM (AMS:DSM) A Risky Investment?

Full year 2022 earnings: EPS exceeds analyst expectations

DSM Firmenich Announces Intention Pay Final Gross Dividend

Consensus EPS estimates fall by 10%

Here's Why We Think Koninklijke DSM (AMS:DSM) Is Well Worth Watching

Is Koninklijke DSM (AMS:DSM) Using Too Much Debt?

Key Executive recently bought €587k worth of stock

Royal DSM NV Sponsored ADR to Be Deleted from OTC Equity

Koninklijke DSM N.V. to Report Fiscal Year 2022 Results on Feb 16, 2023

Estimating The Fair Value Of Koninklijke DSM N.V. (AMS:DSM)

Consensus forecasts updated

Why Koninklijke DSM N.V. (AMS:DSM) Could Be Worth Watching

Avient Corporation (NYSE:AVNT) completed the acquisition of Protective Materials business of Koninklijke DSM N.V. (ENXTAM:DSM)

Is Now The Time To Put Koninklijke DSM (AMS:DSM) On Your Watchlist?

Consensus EPS estimates fall by 17%

Is Koninklijke DSM (AMS:DSM) Using Too Much Debt?

First half 2022 earnings: EPS and revenues exceed analyst expectations

Koninklijke DSM N.V. Announces Interim Dividend

Calculating The Intrinsic Value Of Koninklijke DSM N.V. (AMS:DSM)

Koninklijke DSM N.V. (ENXTAM:DSM) agrees to acquire Prodap Participacoes S/A.

Advent International Corporation and LANXESS Aktiengesellschaft (XTRA:LXS) agreed to acquire Engineering Materials business of Royal DSM from Koninklijke DSM N.V. (ENXTAM:DSM) for €3.9 billion.

Koninklijke DSM N.V. Declares Dividend for the Financial Year 2021, Payable as from 3 June 2022

Public Joint Stock Company KuibyshevAzot (MISX:KAZT) acquired Volgaplast Compounding Ltd from Koninklijke DSM N.V. (ENXTAM:DSM) for RUB119 million.

Upcoming dividend of €1.70 per share

Koninklijke DSM N.V. Reaffirms Earnings Guidance for the Year 2022

Koninklijke DSM (AMS:DSM) Is Increasing Its Dividend To €1.70

Avient Corporation (NYSE:AVNT) entered into agreement to acquire Protective Materials business of Koninklijke DSM N.V. (ENXTAM:DSM) for €1.4 billion ($1.5 billion).

Avient Corporation (NYSE:AVNT) eneteed into agreement to acquire Protective Materials business of DSM

Koninklijke DSM (AMS:DSM) Is Increasing Its Dividend To €1.70

Koninklijke DSM's (AMS:DSM) Upcoming Dividend Will Be Larger Than Last Year's

Koninklijke DSM's (AMS:DSM) Dividend Will Be Increased To €1.70

DSM receives landmark EU market approval for its methane-reducing feed additive Bovaer

Koninklijke DSM (AMS:DSM) Seems To Use Debt Rather Sparingly

Royal DSM Proposes Dividend Increase

Lanxess Reportedly Teams Up with Advent to Bid for DSM's Materials Ops

Koninklijke DSM N.V. (ENXTAM:DSM) completed the acquisition of Vestkorn Milling AS.

Koninklijke DSM N.V. (ENXTAM:DSM) signed an agreement to acquire Vestkorn Milling As for an enterprise value of €65 million.

Are Koninklijke DSM N.V. (AMS:DSM) Investors Paying Above The Intrinsic Value?

We Think Koninklijke DSM (AMS:DSM) Can Stay On Top Of Its Debt

Price target increased to €183

Koninklijke DSM N.V. Receives First Full Market Authorizations for Methane-Reducing Feed Additive Bovaer® for Beef and Dairy in Brazil and Chile

Does This Valuation Of Koninklijke DSM N.V. (AMS:DSM) Imply Investors Are Overpaying?

Koninklijke DSM (AMS:DSM) Has A Pretty Healthy Balance Sheet

Koninklijke DSM N.V.'s (AMS:DSM) Intrinsic Value Is Potentially 17% Below Its Share Price

Independent Deputy Chairwoman of Supervisory Board has left the company

Independent Chairman of Supervisory Board Robert Routs has left the company

Key Executive exercised options and sold €609k worth of stock

Royal DSM Declares Final Dividend for the Financial Year 2020, Payable from 1 June 2021

Upcoming dividend of €1.60 per share

Key Executive recently sold €750k worth of stock

Is Koninklijke DSM (AMS:DSM) A Risky Investment?

Should Koninklijke DSM N.V. (AMS:DSM) Be Part Of Your Dividend Portfolio?

Worthen Industries, Inc. agreed to acquire Advanced Solar Backsheets Business of Koninklijke DSM N.V. from Koninklijke DSM N.V. (ENXTAM:DSM).

Koninklijke Dsm N.V. Announces Board Changes

Are Koninklijke DSM N.V.'s (AMS:DSM) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Analysts update estimates

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS €2.64 (vs €4.27 in FY 2019)

Analysts update estimates

Koninklijke DSM (AMS:DSM) Has Gifted Shareholders With A Fantastic 276% Total Return On Their Investment

New 90-day high: €149